These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31974830)

  • 1. Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.
    Dalziel K; Catchpool M; García-Lorenzo B; Gorostiza I; Norman R; Rivero-Arias O
    Pharmacoeconomics; 2020 May; 38(5):499-513. PubMed ID: 31974830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults.
    Xiong X; Dalziel K; Huang L; Rivero-Arias O
    Value Health; 2023 Jan; 26(1):50-54. PubMed ID: 35970707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm.
    Ratcliffe J; Huynh E; Chen G; Stevens K; Swait J; Brazier J; Sawyer M; Roberts R; Flynn T
    Soc Sci Med; 2016 May; 157():48-59. PubMed ID: 27060541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods.
    Ratcliffe J; Couzner L; Flynn T; Sawyer M; Stevens K; Brazier J; Burgess L
    Appl Health Econ Health Policy; 2011; 9(1):15-27. PubMed ID: 21033766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement Properties of the Online EuroQol-5D-Youth Instrument in Children and Adolescents With Type 1 Diabetes Mellitus: Questionnaire Study.
    Mayoral K; Rajmil L; Murillo M; Garin O; Pont A; Alonso J; Bel J; Perez J; Corripio R; Carreras G; Herrero J; Mengibar JM; Rodriguez-Arjona D; Ravens-Sieberer U; Raat H; Serra-Sutton V; Ferrer M
    J Med Internet Res; 2019 Nov; 21(11):e14947. PubMed ID: 31714252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D.
    Ratcliffe J; Flynn T; Terlich F; Stevens K; Brazier J; Sawyer M
    Pharmacoeconomics; 2012 Aug; 30(8):713-27. PubMed ID: 22788261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
    Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
    Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EQ-5D-Y-5L as a patient-reported outcome measure in psychiatric inpatient care for children and adolescents - a cross-sectional study.
    Åström M; Krig S; Ryding S; Cleland N; Rolfson O; Burström K
    Health Qual Life Outcomes; 2020 Jun; 18(1):164. PubMed ID: 32493419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring health-related quality of life in elementary and secondary school students using the Chinese version of the EQ-5D-Y in rural China.
    Pan CW; Zhong H; Li J; Suo C; Wang P
    BMC Public Health; 2020 Jun; 20(1):982. PubMed ID: 32571279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Health-Related Quality of Life of Australian Adolescents: An Empirical Comparison of the Child Health Utility 9D and EQ-5D-Y Instruments.
    Chen G; Flynn T; Stevens K; Brazier J; Huynh E; Sawyer M; Roberts R; Ratcliffe J
    Value Health; 2015 Jun; 18(4):432-8. PubMed ID: 26091597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
    McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
    Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM; Miyamoto GC; Santos VS; Ben ÂJ; Finch AP; Roudijk B; de Jesus-Moraleida FR; Stein AT; Santos M; Yamato TP
    Pharmacoeconomics; 2024 Sep; 42(9):1047-1063. PubMed ID: 38954389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
    Karim S; Craig BM; Groothuis-Oudshoorn CGM
    Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D.
    Wille N; Badia X; Bonsel G; Burström K; Cavrini G; Devlin N; Egmar AC; Greiner W; Gusi N; Herdman M; Jelsma J; Kind P; Scalone L; Ravens-Sieberer U
    Qual Life Res; 2010 Aug; 19(6):875-86. PubMed ID: 20405245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.